Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Merck - Caught on Camera

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s most important trials are “coming to a head” over the coming months. Levy said the company is

MarketBeat

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets. Peters said Exelixis’ guidance

MarketBeat

Dow Hits New High as Warsh Takes Fed Oath: Stock Market Today

President Donald Trump welcomed Fed Chair Kevin Warsh the same way President Ronald Reagan welcomed Fed Chair Alan Greenspan.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck KGaA Q1 Earnings Call Highlights

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

MarketBeat

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee

MarketBeat

Clinical trials that are actually marketing ploys targeting doctors – how seeding trials put profit over patients

Some clinical trials aren’t designed to answer scientific questions. They’re designed to market drugs. In our recently published research, my team and I analyzed over 34,000 industry-funded trials and found that hundreds of studies across seven medical fields were likely designed to promote a drug to physicians rather than to…

The Conversation

Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Barchart

Read news from The Economist, FT, and more,
with one subscription

This Merck (MRK) Stock Bullish Diagonal Trade Targets a Price of $130 by June 18

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Barchart

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MarketBeat

3 Undervalued Names Too Cheap to Ignore

Three prominent names across the biopharma and consumer staples spaces offer the potential for value plays with room for fundamental growth as well.

MarketBeat

Experimental pill may offer new cholesterol-lowering option for millions

There are other pills that patients can add to their statin

The Independent UK

Promising vaccine for aggressive melanoma could unlock the body’s potential to fight cancer

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

Euronews

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, pharmaceutical companies Moderna and Merck announced in five-year findings.

The Independent UK

3 “Forever Stocks” to Hold When the Market Won’t Sit Still

Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

We Got This Covered

Today in ‘great’ America: Donald Trump decides to prove he can’t negotiate to save his life

What an awful deal.

The Guardian - UK

Life-saving therapies are being delayed as research funding dries up

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

The Independent UK

More drug companies sign on to Trump’s health exchange that promises to lower prescription prices

Administration officials say the ‘Trump Rx’ website should be up and running next month

Evening Standard

Boss of drugs giant GSK declares US best place to invest

Dame Emma Walmsley said the US was still leading the way for new drugs and vaccines.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

What will be the cost of Keir Starmer’s new medicines deal with Donald Trump? British lives

More than £3bn that could have been used for UK patients will go to big pharma for its branded products, says Guardian columnist Aditya Chakrabortty

MarketBeat

Dividend Stocks for 2026: Where to Invest as the Market Cools

These three dividend heavyweights offer attractive yields and upside potential heading into what could be an uncertain 2026.

The Independent UK

FDA opens safety review of injectable RSV drugs approved for babies and toddlers

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV virus

Barchart

These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now

Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.

Barchart

2 Dividend Stocks to Buy Now for Big Payout Growth Ahead

Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.

Barchart

The Dow Jones Looks Ready for Death, But These 3 Blue-Chip Stocks Have More Life (and Gains) Ahead

These three stocks have healthy charts in an index that’s looking sick.

MarketBeat

Healthcare Rotation Underway: 3 Stocks Leading the Charge

Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.